o NoneEntity Type
0001389545
NovaCal Pharmaceuticals, Inc.
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 NovaBay Pharmaceuticals, Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 NovaBay Pharmaceuticals, Inc. 
Street Address 1Street Address 2
 2000 POWELL STREET, SUITE 1150 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 EMERYVILLE CALIFORNIA 94608 (510) 899-8800 



3. Related Persons
Last NameFirst NameMiddle Name
HALLJUSTIN
Street Address 1Street Address 2
2000 POWELL STREETSUITE 1150
CityState/Province/CountryZIP/Postal Code
EMERYVILLEOHIO94608
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 PRESIDENT, CHIEF EXECUTIVE OFFICER AND GENERAL COUNSEL

Last NameFirst NameMiddle Name
CHRISTOPHERLYNN
Street Address 1Street Address 2
2000 POWELL STREETSUITE 1150
CityState/Province/CountryZIP/Postal Code
EMERYVILLECALIFORNIA94608
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 INTERIM CHIEF FINANCIAL OFFICER

Last NameFirst NameMiddle Name
FREIMANPAUL
Street Address 1Street Address 2
2000 POWELL STREETSUITE 1150
CityState/Province/CountryZIP/Postal Code
EMERYVILLECALIFORNIA94608
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
WUMIJIA (BOB)
Street Address 1Street Address 2
2000 POWELL STREETSUITE 1150
CityState/Province/CountryZIP/Postal Code
EMERYVILLECALIFORNIA94608
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
ZHENGYENYOU (JEFF)
Street Address 1Street Address 2
2000 POWELL STREETSUITE 1150
CityState/Province/CountryZIP/Postal Code
EMERYVILLECALIFORNIA94608
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
WANGXIAOPEI (RAY)
Street Address 1Street Address 2
2000 POWELL STREETSUITE 1150
CityState/Province/CountryZIP/Postal Code
EMERYVILLECALIFORNIA94608
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
SITSWAN
Street Address 1Street Address 2
2000 POWELL STREETSUITE 1150
CityState/Province/CountryZIP/Postal Code
EMERYVILLECALIFORNIA94608
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
LIXINZHOU (PAUL)
Street Address 1Street Address 2
2000 POWELL STREETSUITE 1150
CityState/Province/CountryZIP/Postal Code
EMERYVILLECALIFORNIA94608
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale   x First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $   USD x Indefinite
Total Amount Sold $ 0 USD 
Total Remaining to be Sold $   USD x Indefinite
 
Clarification of Response (if Necessary)
 SEE THE DESCRIPTION OF THE INTERNATIONAL DISTRIBUTION AGREEMENT, DATED APRIL 16, 2020, REGARDING THE WARRANTS TO BE ISSUED THEREUNDER IN THE FORM 8-K FILED WITH THE SEC ON APRIL 20, 2020.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 0


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to May 2024 Click Here for more NovaBay Pharmaceuticals Charts.
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more NovaBay Pharmaceuticals Charts.

Novabay Pharmaceuticals, Inc. News

NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
Monday 22 April 2024 (1 week ago) • Business Wire
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
Saturday 20 April 2024 (2 weeks ago) • Business Wire
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
Wednesday 17 April 2024 (2 weeks ago) • Business Wire
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
Wednesday 27 March 2024 (1 month ago) • Business Wire
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
Tuesday 26 March 2024 (1 month ago) • Business Wire
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
Thursday 14 March 2024 (2 months ago) • Business Wire
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (2 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 7 February 2024 (3 months ago) • Edgar (US Regulatory)
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
Wednesday 31 January 2024 (3 months ago) • Business Wire
Form 8-K - Current report
Thursday 11 January 2024 (4 months ago) • Edgar (US Regulatory)
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Wednesday 10 January 2024 (4 months ago) • Business Wire
Form D - Notice of Exempt Offering of Securities
Friday 5 January 2024 (4 months ago) • Edgar (US Regulatory)

More Novabay Pharmaceuticals, Inc. News Articles